Myelofibrosis  >>  itacitinib (INCB039110)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
itacitinib (INCB039110) / Incyte
NCT01633372: An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis

Completed
2
87
Canada, US, RoW
itacitinib, INCB039110
Incyte Corporation
MPN (Myeloproliferative Neoplasms)
12/13
06/21
NCT03144687: A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis

Completed
2
23
Europe, US
Itacitinib, INCB039110, Ruxolitinib, INCB018424, Jakafi, Jakavi
Incyte Corporation
MPN (Myeloproliferative Neoplasms)
03/20
06/21
2017-005109-11: A study evaluating the impact of Itacitinib alone or when added to ruxolitinib for the treatment of myelofibrosis

Not yet recruiting
2
42
Europe
Itacitinib, INCB039110, Modified-release tablet
Incyte Corporation, Incyte Corporation
Myelofibrosis, Myelofibrosis, Diseases [C] - Cancer [C04]
 
 
NCT04640025: A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib

Active, not recruiting
2
18
Europe, Canada, US, RoW
itacitinib, INCB039110
Incyte Corporation
Myelofibrosis, Postlung Transplant (Bronchiolitis Obliterans), Chronic Graft Versus Host Disease
06/26
06/26

Download Options